Overview

A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus

Status:
Completed

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

- 1. There is no standard treatment option for non-clear cell renal cell carcinoma (RCC). - 2. Patients with non-clear cell RCC is strongly assumed to have benefit from anti-VEGF treatment. - 3. There is no trial of axitinib for non-clear cell RCC. - 4. Axitinib is expected to show more potent efficacy over sorafenib or sunitinib in renal cell carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Seoul National University Hospital

Collaborator:

Pfizer

Treatments:

Axitinib
Everolimus
Sirolimus